Article

Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer

Author(s):

Lecia V. Sequist

Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).

Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Image of two people.
Related Content
Image of two doctors with text.
June 13th 2025

Updates in Shared Decision-Making in Lung Cancer Following ASCO 2025

Ryan Scott
Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert oncologists.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
FDA granted priority review to Zepzelca plus Tecentriq in extensive-stage small cell lung cancer: © stock.adobe.com.
June 11th 2025

FDA Grants Priority Review to Zepzelca Combo for Small Cell Lung Cancer

Spencer Feldman
FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of lungs.
Published: June 8th 2025 | Updated: June 8th 2025

Detailing the Potential Benefit of Intratumoral Therapies in Lung Cancer

Ryan Scott
Dr. Jared Weiss walks patients through the therapeutic potential viability of intratumoral therapies among those with lung cancer.
image of lungs
June 8th 2025

Targeted Chemo Improves Survival in Early-Stage Lung Cancer

Jordyn Sava
Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous lung cancer.